These findings were in agreement with Izquierdo et al. [45], who demonstrated the efficacy of paricalcitol therapy in reducing the levels of inflammatory markers including TNF-α, IL-6, CRP, and IL-18 in patients with kidney disease. Here, CRP is linked to kidney disorder.